• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Technologies
    • Balloons
    • Brain-computer interfaces
    • Cardiac Implants
    • Catheters
    • Endoscopes
    • Heart valves
    • Pulsed Field Ablation
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Molding
      • Injection Molding
      • Insert molding
      • Mold Components
    • Tools
  • Materials
    • Advanced Materials
    • Metals
    • Nitinol
    • Plastics
    • Silicone
  • Business
    • Distribution Agreements
    • Legal News
    • Mergers & Acquisitions
    • Partnerships
    • Personnel Moves
  • Regulatory
    • 510(k)
    • CE Mark
    • FDA Breakthrough Designation
    • ISO Certification
    • Pre-Market Approval (PMA)
    • Recalls
  • Suppliers
  • About Us

Abbott Xience stent gains expanded CE mark

April 6, 2021 By Sean Whooley

AbbottAbbott (NYSE:ABT) announced today that its Xience stent received CE mark approval for a shorter duration of dual anti-platelet therapy (DAPT).

The European approval for the stent allows for the DAPT to go as short as 28 days, the shortest indication available in the world for patients with high bleeding risk (HBR), according to a news release.

Abbott Park, Ill.-based Abbott said approval follows study results that demonstrated both one-month or three-month DAPT followed by aspirin monotherapy is safe in HBR patients and is intended to improve patient outcomes while providing more treatment options to physicians and patients.

The Xience 28 and Xience 90 clinical trials evaluated more than 3,600 participants from Europe, the Americas and Asia across the two different DAPT durations in exclusively HBR patients. The results proved consistent and demonstrated that those who receive the Xience stent with shorter DAPT durations do not have an increase in cardiac events and showed a reduction in severe bleeding.

Xience is the only stent to have evidence and data for both one-month and three-months DAPT, followed by two different types of blood-thinning medication in HBR patients, Abbott said. The company is seeking an indication for HBR for the Xience stent in the U.S., too.

“In patients with high bleeding risk, the XIENCE stent has proven that it can ensure patient safety without compromising efficacy when duration of blood-thinning medications is shortened,” Abbott vascular business CMO & divisional VP of global medical affairs Dr. Nick West said in the release. “These findings build on the unrivaled volume of research confirming the XIENCE stent’s leading performance across a range of patient and clinical situations.”

Filed Under: Implants Tagged With: Abbott, Abbott Vascular

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“mte
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest trends and developments in medical tubing and extrusion.
MDO ad

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World
Drug Delivery Business News

Medical Tubing + Extrusion

Subscribe to our E-Newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS